EPISODE · Mar 3, 2022 · 24 MIN
Biocon's Biosimilar Blues
from The Morning Brief · host The Economic Times
Biocon’s recent acquisition of its partner Viatris Inc.'s biosimilar business has shocked the investors as the company’s shares fell nearly 12% on the bourses. Host Dia Rekhi along with Biocon Biologics’ Deputy CEO Shreehas Tambe, ET’s Kiran Somvanshi, and ET Prime’s Vikas Dandekar break down the deal means for the company and the investors and whether the $3.3-billion bet is worth the risk? Credits: ET NowSee omnystudio.com/listener for privacy information.
NOW PLAYING
Biocon's Biosimilar Blues
No transcript for this episode yet
Similar Episodes
Mar 26, 2026 ·1m
Mar 19, 2026 ·34m
Feb 18, 2026 ·11m
Feb 11, 2026 ·45m